Study on the Therapeutic Efficacy of Subcutaneous Semaglutide Injection in Patients with Fatty Liver Complicated by Obesity

Study on the Therapeutic Efficacy of Subcutaneous Semaglutide Injection in Patients with Fatty Liver Complicated by Obesity - Study on the Therapeutic Efficacy of Subcutaneous Semaglutide Injection in Patients with Fatty Liver Complicated by Obesity

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052061

Enrollment

Registered

2024-01-01

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver Complicated by Obesity

Interventions

Subcutaneous Semaglutide Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients who will be treated with subcutaneous semaglutide for fatty liver complicated by obesity, who understand the nature of this study and give written consent will be included.

Exclusion criteria

Exclusion criteria: Those who cannot give consent for this study, or those who are expected to have a poor long-term prognosis due to liver failure or malignancy

Design outcomes

Primary

Measure	Time frame
Whether or not obesity and fatty liver are improved, and information on side effects	—

Countries

Japan

Contacts

Public ContactNorihiro Imai

Nagoya University Graduate School of Medicine Department of Gastroenterology and Hepatology

norihiro@med.nagoya-u.ac.jp0527442169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026